Commercial-scale synthetic peptide substances manufactured under cGMP controls with comprehensive analytical verification.
Combining 20 years of technical management depth with industrial-scale infrastructure to de-risk complex biotherapeutic development.
Proficient in both SPPS (Solid-Phase Peptide Synthesis) and LPPS (Liquid-Phase Peptide Synthesis), allowing efficient assembly of extended sequences exceeding 40 amino acids, including cyclic and lipid-conjugated peptides.
Equipped with multi-column industrial chromatographic separation suites to resolve critical diastereomeric impurities, truncated peptides, and D-amino acid racemization variants with maximum recovery rates.
Full support for global registration filings (US FDA DMF, EDMF/ASMF, NMPA) with stability data according to ICH Q1A guidelines, validated analytical assays, and complete process impurity trace reports.
A comprehensive examination of supply chain resilience, Chinese manufacturing economics, and clinical development compliance.
The global peptide therapeutics industry is experiencing an unprecedented demand inflection, primarily catalyzed by multi-target incretin mimetics (GLP-1/GIP/Glucagon agonists such as Tirzepatide, Retatrutide, and Semaglutide) and sustained-release oncology treatments. As therapeutic dosages climb into the multi-milligram range, pharmaceutical procurement organizations face immense pressure regarding raw material availability, synthesis costs, and batch uniformity.
Chinese GMP peptide manufacturing facilities have positioned themselves as the critical manufacturing backbone for global biopharma through distinct structural advantages:
Navigating international regulatory waters requires peptide contract manufacturers to adhere strictly to the International Council for Harmonisation (ICH) guidelines. For pharmaceutical buyers across North America, Europe, and the APAC region, supply qualification extends far beyond purchasing price per gram.
A competent peptide API partner must actively eliminate key downstream risks:
From metabolic syndromes and immune health to advanced cosmetic formulations, our modular CDMO infrastructure supports targeted sector requirements.
High-volume synthesis of GLP-1, GIP, and Glucagon receptor agonist APIs (Semaglutide, Tirzepatide, Retatrutide). Engineered with scalable lipid side-chain acylation protocols and reliable counter-ion conversion techniques.
Production of high-potency immune modulators such as Thymosin Alpha 1 and Thymalin. Stringent process control ensures batch consistency and prevents degradation in therapeutic peptides designed for cellular defense enhancement.
Specialized synthesis of GnRH and LHRH analogues (Triptorelin, Deslorelin) tailored for depot injection formulations, requiring tight control over particle morphology, residual TFA levels, and polymorph behavior.
Production of high-stability cosmetic signal, carrier, and anti-aging peptides. Supplied in pure, non-toxic salt forms (acetate, hydrochloride) compatible with high-end cosmetic emulsions and dermal delivery systems.
Advanced generic and customized peptides produced with documented traceability and complete batch analytical certificates.
Essential guidance covering quality verification, regulatory compliance, and procurement timelines.
Research-grade peptides are typically intended for early in vitro screening and non-regulated laboratory studies. They rely on standard purity checks without formal process validation. In contrast, cGMP-grade peptides are manufactured under strict regulatory controls, including validated cleanrooms, audited computerized systems, comprehensive batch records, qualified starting materials, validated analytical methods, stability testing, and complete traceability. This documentation supports formal clinical trials (IND/NDA/ANDA submissions).
TFA is commonly introduced during peptide resin cleavage. Because residual TFA may cause cellular toxicity in therapeutic applications, our cGMP downstream process incorporates validated ion-exchange chromatography or repeated lyophilization from mild acetic acid or hydrochloric acid buffers. We provide precise counter-ion quantification (acetate, chloride, or sodium) via ion chromatography (IC) or 19F-NMR to align with target drug product specifications.
Every commercial batch is accompanied by an extensive Certificate of Analysis (CoA) containing reversed-phase HPLC purity profiles, high-resolution mass spectrometry (HRMS) identity confirmation, net peptide content via amino acid analysis (AAA) or nitrogen determination, water content (Karl Fischer), residual solvents via Headspace GC-MS, heavy metals (ICP-MS), bioburden, and bacterial endotoxin measurements.
With an integrated synthetic footprint reaching multi-ton annual capacities, our Hangzhou manufacturing facility utilizes high-volume solid-phase peptide reactors (ranging up to 1,000L) alongside high-capacity preparative HPLC columns. This infrastructure enables reliable multi-kilogram to commercial ton batch yields for complex peptides, including Semaglutide, Tirzepatide, and other metabolic mimetics.
Peptide APIs are lyophilized into high-density, moisture-resistant bulk glass or HDPE pharmaceutical containers with inert nitrogen overlay and double polyethylene liners. Global shipments are coordinated via dedicated temperature-controlled cold-chain logistics (monitored -20°C or 2-8°C containers with continuous GPS and data-logging sensors) handled by our specialized regional export desks.
Thin